1.
J Med Chem
; 52(22): 6958-61, 2009 Nov 26.
Artículo
en Inglés
| MEDLINE
| ID: mdl-19860433
RESUMEN
The design, synthesis, and biological characterization of an orally active prodrug (3) of gemcitabine are described. Additionally, the identification of a novel co-crystal solid form of the compound is presented. Valproate amide 3 is orally bioavailable and releases gemcitabine into the systemic circulation after passing through the intestinal mucosa. The compound has entered clinical trials and is being evaluated as a potential new anticancer agent.